FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026908838> ?p ?o ?g. }

• W2026908838 endingPage "1355" @default.
• W2026908838 startingPage "1347" @default.
• W2026908838 abstract "Chronic inhalation bioassays in rodents are used to assess pulmonary carcinogenicity for purposes of hazard identification and potentially for risk characterization. The influence of high experimental doses on tumor development has been recognized for some time and has led to the concept of maximum tolerated dose (MTD) for dose selection, with the highest dose being at the MTD. Exposure at the MTD should ensure that the animals are sufficiently challenged while at the same time the animal's normal longevity is not altered from effects other than carcinogenicity. A characteristic of exposure-dose-response relationships for chronically inhaled particles is that lung tumors are significantly increased only at high exposure levels, and that lung tumors are seen in rats only but not in mice or hamsters. This lung tumor response in rats is thought to be secondary to persistent alveolar inflammation, indicating that the MTD may have been exceeded. Thus, mechanisms of toxicity and carcinogenicity may be dose dependent and may not operate at lower doses that humans normally experience. Despite awareness of this problem, carcinogenicity bioassays that evaluate particulate compounds in rodents have not always been designed with the MTD concept in mind. This is due to several problems associated with determining an appropriate MTD for particle inhalation studies. One requirement for the MTD is that some toxicity should be observed. However, it is difficult to define what degree of toxic response is indicative of the MTD. For particle inhalation studies, various noncancer end points in addition to mortality and body weight gain have been considered as indicators of the MTD, i.e., pulmonary inflammation, increased epithelial cell proliferation, increased lung weight, impairment of particle clearance function, and significant histopathological findings at the end of a subchronic study. However, there is no general agreement about quantification of these end points to define the MTD. To determine whether pulmonary responses are indicative of the MTD, we suggest defining an MTD based on results of a multidose subchronic and chronic inhalation study with a known human particulate carcinogen, e.g., asbestos or crystalline silica. Quantification of effects in such a study using the noncancer end points listed above would identify a dose level without significant signs of toxicity at the end of the subchronic study. If this dose level still results in significant lung tumor incidence at the end of the chronic study. We will have a sound basis for characterizing the MTD and justifying its use in future particle inhalation studies. Also, a better understanding of cellular and molecular mechanisms of particle-induced lung tumors is needed to support the MTD concept." @default.
• W2026908838 created "2016-06-24" @default.
• W2026908838 creator A5016697206 @default.
• W2026908838 date "1997-09-01" @default.
• W2026908838 modified "2023-10-06" @default.
• W2026908838 title "Pulmonary carcinogenicity of inhaled particles and the maximum tolerated dose." @default.
• W2026908838 cites W1583960494 @default.
• W2026908838 cites W1597643123 @default.
• W2026908838 cites W1676612259 @default.
• W2026908838 cites W1843560668 @default.
• W2026908838 cites W1853908240 @default.
• W2026908838 cites W1967627528 @default.
• W2026908838 cites W1969030685 @default.
• W2026908838 cites W1974678821 @default.
• W2026908838 cites W1988742153 @default.
• W2026908838 cites W2020730771 @default.
• W2026908838 cites W2030647754 @default.
• W2026908838 cites W2039935804 @default.
• W2026908838 cites W2046067485 @default.
• W2026908838 cites W2054977824 @default.
• W2026908838 cites W2058203984 @default.
• W2026908838 cites W2063943133 @default.
• W2026908838 cites W2065545414 @default.
• W2026908838 cites W2093626911 @default.
• W2026908838 cites W2101245680 @default.
• W2026908838 cites W2111795581 @default.
• W2026908838 cites W2113637303 @default.
• W2026908838 cites W2122713184 @default.
• W2026908838 cites W2122806458 @default.
• W2026908838 cites W2134896722 @default.
• W2026908838 cites W29135332 @default.
• W2026908838 doi "https://doi.org/10.1289/ehp.105-1470142" @default.
• W2026908838 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1470142" @default.
• W2026908838 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9400749" @default.
• W2026908838 hasPublicationYear "1997" @default.
• W2026908838 type Work @default.
• W2026908838 sameAs 2026908838 @default.
• W2026908838 citedByCount "18" @default.
• W2026908838 countsByYear W20269088382014 @default.
• W2026908838 countsByYear W20269088382015 @default.
• W2026908838 countsByYear W20269088382018 @default.
• W2026908838 countsByYear W20269088382020 @default.
• W2026908838 crossrefType "journal-article" @default.
• W2026908838 hasAuthorship W2026908838A5016697206 @default.
• W2026908838 hasBestOaLocation W20269088381 @default.
• W2026908838 hasConcept C104488531 @default.
• W2026908838 hasConcept C114246631 @default.
• W2026908838 hasConcept C126322002 @default.
• W2026908838 hasConcept C178790620 @default.
• W2026908838 hasConcept C185592680 @default.
• W2026908838 hasConcept C2776954882 @default.
• W2026908838 hasConcept C2777334693 @default.
• W2026908838 hasConcept C2777714996 @default.
• W2026908838 hasConcept C2779777708 @default.
• W2026908838 hasConcept C2781047374 @default.
• W2026908838 hasConcept C29730261 @default.
• W2026908838 hasConcept C33070731 @default.
• W2026908838 hasConcept C42219234 @default.
• W2026908838 hasConcept C42407357 @default.
• W2026908838 hasConcept C54355233 @default.
• W2026908838 hasConcept C71924100 @default.
• W2026908838 hasConcept C86803240 @default.
• W2026908838 hasConcept C98274493 @default.
• W2026908838 hasConceptScore W2026908838C104488531 @default.
• W2026908838 hasConceptScore W2026908838C114246631 @default.
• W2026908838 hasConceptScore W2026908838C126322002 @default.
• W2026908838 hasConceptScore W2026908838C178790620 @default.
• W2026908838 hasConceptScore W2026908838C185592680 @default.
• W2026908838 hasConceptScore W2026908838C2776954882 @default.
• W2026908838 hasConceptScore W2026908838C2777334693 @default.
• W2026908838 hasConceptScore W2026908838C2777714996 @default.
• W2026908838 hasConceptScore W2026908838C2779777708 @default.
• W2026908838 hasConceptScore W2026908838C2781047374 @default.
• W2026908838 hasConceptScore W2026908838C29730261 @default.
• W2026908838 hasConceptScore W2026908838C33070731 @default.
• W2026908838 hasConceptScore W2026908838C42219234 @default.
• W2026908838 hasConceptScore W2026908838C42407357 @default.
• W2026908838 hasConceptScore W2026908838C54355233 @default.
• W2026908838 hasConceptScore W2026908838C71924100 @default.
• W2026908838 hasConceptScore W2026908838C86803240 @default.
• W2026908838 hasConceptScore W2026908838C98274493 @default.
• W2026908838 hasIssue "suppl 5" @default.
• W2026908838 hasLocation W20269088381 @default.
• W2026908838 hasLocation W20269088382 @default.
• W2026908838 hasLocation W20269088383 @default.
• W2026908838 hasLocation W20269088384 @default.
• W2026908838 hasOpenAccess W2026908838 @default.
• W2026908838 hasPrimaryLocation W20269088381 @default.
• W2026908838 hasRelatedWork W2010787626 @default.
• W2026908838 hasRelatedWork W2021564288 @default.
• W2026908838 hasRelatedWork W2026908838 @default.
• W2026908838 hasRelatedWork W2034813847 @default.
• W2026908838 hasRelatedWork W2081068877 @default.
• W2026908838 hasRelatedWork W2094688805 @default.
• W2026908838 hasRelatedWork W2097739428 @default.
• W2026908838 hasRelatedWork W2152218173 @default.
• W2026908838 hasRelatedWork W2391790964 @default.
• W2026908838 hasRelatedWork W4210615633 @default.

• next